|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Everelimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies显示文摘 | Vitko S Tedesco H Eris J | 2004 | Am J Transplant2004，4，： | 1 |
| 2 | Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation 显示文摘 | Langer RM Hen6 R Vitko S | 2012 | Transpl Int2012，25，5： | 1 |
| 3 | Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation:results of the Atlas study显示文摘 | Vitko S Klinger M Salmela K | | 0，，12： | 1 |
| 4 | Everolimus plus early tacrolimus minization: a phase II, randomized, open - labed, muhicentre trial in renal transplantation 显示文摘 | Langer RM Hen6 R Vitko S | 2012 | Transpl Int2012，25，5： | 1 |
| 5 | Cy- closporine withdrawal from a mycophenolate mofetil-contai- ning immunosuppressive regimen: results of a five-year, prospective, randomized study 显示文摘 | Abramowicz D Del Carmen Rial M Vitko S | 2005 | J Am Soc Nephrol2005，16，7： | 1 |
| 6 | Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation:results of the Atlas study显示文摘 | Vitko S Klinger M Salmela K | 2005 | Transplantation2005，80，12： | 1 |
| 7 | Cyclosporine renal dysfunction显示文摘 | Vitko S Viklicky O | 2004 | Transplant Proc2004，36，2： | 1 |
| 8 | Three-year efficacy andsafety results from a study of everolimus versus mycophenolate mofetilin de novo renal transplant patients 显示文摘 | Vitko S Margreiter R Weimar W | 2005 | American Journal ofTransplantation2005，5，10： | 1 |
| 9 | 12- month safety and efficacy of everolimus with reduced exposure cyclosporine in de rtovo renal transplant recipients显示文摘 | TEDESCO-SILVA H Jr VITKO S PASCUAL J et ol | 2007 | Transpl Int2007，20，1： | 1 |
| 10 | Everolimus (certican) 12-month safety and efficacy versus mycophenolate mofetil in de Novo renal transplant reeipients显示文摘 | Vitko S Margreiter R Weimar W | 2004 | Transplantation2004，78，11： | 1 |
| 11 | Three-year efficacy and safety results from a study of everolirnus versus mycophe nolate mofetil in de novo renal transplant patients显示文摘 | Vitko S Margreiter R Weimar W el al | 2005 | Am J Transplant2005，5，10： | 1 |
| 12 | Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study 显示文摘 | Abramowicz D del Carmen Rial M Vitko S | 2005 | J Am Soc Nephrol2005，16，7： | 1 |
| 13 | Everolimus plus early tacrolimus minimization:a phaseⅢ,randomized,open-label,multicentre trial in renal transplantation显示文摘 | Langer RM Hene R Vitko S | 2012 | Transpl Int2012，25，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员